Influence of ABO blood groups on primary hemostasis

Transfusion

Volumn 41, Issue 1, 2001, Pages 56-60

  Moeller, Ansgar ^a   Weippert Kretschmer, Monika ^a   Prinz, Helge ^a   Kretschmer, Volker ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR;

ARTICLE; BLEEDING TIME; BLOOD GROUP ABO SYSTEM; BLOOD TRANSFUSION; DIAGNOSTIC VALUE; FEMALE; HEMOSTASIS; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; NORMAL HUMAN; PATHOPHYSIOLOGY; VON WILLEBRAND DISEASE;

ABO BLOOD-GROUP SYSTEM; BLEEDING TIME; FEMALE; HEMOSTASIS; HUMANS; MALE; REFERENCE VALUES; VON WILLEBRAND FACTOR;

EID: 0035122210     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2001.41010056.x     Document Type: Article

References (45)

1. Von Willebrand factor and von Willebrand disease
2. The effect of ABO blood group on the diagnosis of von Willebrand disease
3. Platelet function analyzer (PFA-100™) in the screening of type I von Willebrand disease
4. Factor VIII and factor IX in a twin population. Evidence for a major effect of ABO locus on factor VIII level
5. Genetics of plasma concentration of von Willebrand factor
6. The blood groups in relation to peptic ulceration and carcinoma of colon, rectum, breast and bronchus
7. Influence of the ABO blood groups and secretor status on bleeding and on perforation of duodenal ulcer
8. ABO blood groups in gastric bleeding
9. Blood groups and alimentary disorders
10. Erythrocyte rheology in acute cerebral thrombosis. Effects of ABO blood groups
11. Von Willebrand factor in plasma: A novel risk factor for recurrent myocardial infarction and death
12. Role of clotting factor VIII in effect of von Willebrand factor on ocurrence of deep-vein thrombosis
13. Factor VIII, ABO blood group and the incidence of ischaemic heart disease
14. Zusammenhang zwischen ABO-blutgruppe und thromboseneigung
15. ABO blood group and ischaemic heart disease in British men
16. Detection of abnormal platelet function with an in vitro model of primary haemostasis
17. Simulation of primary hemostasis in vitro
18. Evaluation of an in vitro bleeding time device, Thrombostat 4000
19. Variables influencing the Thrombostat 4000: Recommended standardization
20. In vitro bleeding test - A simple method for the detection of aspirin effects on platelet function
21. Clinical implications of the in vitro test - A review
22. Determination and treatment of disorders of primary haemostasis - Experience with routine application of the in vitro bleeding test
23. The Thrombostat 4000 - A sensitive screening test for von Willebrand's disease
24. Standardization of the PFA-100® platelet function test in 105 mmol/l buffered citrate: Effect of gender, smoking and oral contraceptives
25. Evaluation of platelet function by PFA-100™
26. The platelet function analyzer (PFA-100™): A novel in-vitro system for evaluation of primary haemostasis in children
27. Evaluation of the PFA-100 system in the diagnosis and therapeutic monitoring of patients with von Wilebrand disease
28. PFA-100™ system: A new method for assessment of platelet dysfunction
29. Performance of the platelet function analyzer (PFA-100™) in clinical practice
30. Therapeutic monitoring of von Willebrand disease: Interest and limits of a platelet function analyser at high shear stress
31. Performance of the platelet function analyzer PFA-100™ in testing abnormalities of primary haemostasis
32. Preliminary data from a field trial of the PFA- 100™ system
33. A comparison of the effects of aspirin on bleeding time measured using the Simplate method and closure time measured using the PFA-100, in healthy volunteers
34. PFA-100™ system: A sensitive screening test for platelet-related hemostasis defects
35. PFA-100™ prorides a rapid screening test to identify children with severe bleeding disorders
36. Easy testing of platelet function in children by means of the PFA-100™
37. Hemostaseological management of urological operations in patients taking aspirin using the Thrombostat 4000
38. Platelet function analyzer (PFA- 100™) for screening of von Willebrand disease (vWD) (abstract)
39. Evaluation of ristocetin-Willebrand factor assay and ristocetin-induced platelet aggregation
40. Luminographic detection of von Willebrand factor multimers in agarose gels and on nitrocellulose membranes
41. The plasma concentration of factor VIII in the normal population. The effects of age, sex and blood group
42. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII in patients with von Willebrand's disease
43. Bleeding time, blood groups and von Willebrand factor
44. The bleeding time in normal subjects is mainly determined by platelet von Willebrand factor and is independent from blood group